American Century Companies Inc. Buys 17,855 Shares of Intellia Therapeutics, Inc. $NTLA

American Century Companies Inc. raised its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 3.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 471,676 shares of the company’s stock after acquiring an additional 17,855 shares during the quarter. American Century Companies Inc. owned about 0.46% of Intellia Therapeutics worth $3,354,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. GF Fund Management CO. LTD. bought a new stake in shares of Intellia Therapeutics during the fourth quarter worth approximately $25,000. Harbour Investments Inc. lifted its holdings in Intellia Therapeutics by 76.7% during the 1st quarter. Harbour Investments Inc. now owns 5,214 shares of the company’s stock worth $37,000 after purchasing an additional 2,264 shares during the last quarter. 49 Wealth Management LLC bought a new stake in Intellia Therapeutics in the 1st quarter valued at $74,000. Corton Capital Inc. acquired a new position in Intellia Therapeutics in the 1st quarter valued at $92,000. Finally, Tower Research Capital LLC TRC increased its position in Intellia Therapeutics by 28.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,148 shares of the company’s stock worth $95,000 after buying an additional 1,808 shares during the period. 88.77% of the stock is currently owned by institutional investors and hedge funds.

Intellia Therapeutics Stock Down 2.2%

NTLA stock opened at $11.35 on Friday. The company’s 50-day moving average price is $11.28 and its two-hundred day moving average price is $9.58. The firm has a market cap of $1.22 billion, a P/E ratio of -2.42 and a beta of 2.31. Intellia Therapeutics, Inc. has a 12 month low of $5.90 and a 12 month high of $23.76.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.99) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.03) by $0.04. The company had revenue of $14.25 million during the quarter, compared to the consensus estimate of $12.26 million. Intellia Therapeutics had a negative net margin of 908.48% and a negative return on equity of 57.48%. The firm’s quarterly revenue was up 104.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.52) EPS. Equities analysts predict that Intellia Therapeutics, Inc. will post -5.07 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on NTLA. HC Wainwright dropped their target price on Intellia Therapeutics from $30.00 to $25.00 and set a “buy” rating for the company in a report on Friday, August 8th. Guggenheim reiterated a “buy” rating and issued a $14.00 price objective on shares of Intellia Therapeutics in a research note on Wednesday, August 13th. Canaccord Genuity Group cut their price objective on shares of Intellia Therapeutics from $74.00 to $54.00 and set a “buy” rating for the company in a report on Tuesday, June 3rd. Royal Bank Of Canada lowered their target price on shares of Intellia Therapeutics from $25.00 to $21.00 and set an “outperform” rating on the stock in a report on Friday, August 8th. Finally, Wedbush reiterated a “neutral” rating and issued a $7.00 price target on shares of Intellia Therapeutics in a research note on Monday, June 16th. Twelve equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Intellia Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.05.

Insider Buying and Selling at Intellia Therapeutics

In other Intellia Therapeutics news, Director William J. Chase purchased 100,000 shares of the stock in a transaction dated Wednesday, August 20th. The stock was bought at an average price of $10.03 per share, with a total value of $1,003,000.00. Following the acquisition, the director owned 134,693 shares of the company’s stock, valued at approximately $1,350,970.79. This represents a 288.24% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Edward J. Dulac III sold 7,462 shares of the company’s stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $14.02, for a total value of $104,617.24. Following the sale, the executive vice president owned 106,062 shares of the company’s stock, valued at approximately $1,486,989.24. This represents a 6.57% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 12,534 shares of company stock valued at $153,837 over the last 90 days. Corporate insiders own 3.10% of the company’s stock.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.